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Abstract
Background: The association between serum Retinol Binding Protein 4 (RBP4) and obesity is still controversial.
Serum RBP4 levels varies by gender, and estradiol may play a role in the difference. To investigate the participation
of sex hormones in the association of RBP4 and obesity in humans, we measured serum RBP4, BMI, and sex hormones
in 87 women from the outpatient.
Methods: Eighty-seven subjects of Chinese women origin from the outpatient (aged 40.22 ± 15.54 years) were
enrolled. Subjects with diseases affecting the metabolic state or not suitable to participate in this study were excluded.
Anthropometrics and laboratory tests, including lipid profile, luteinizing hormone (LH), follicle stimulating hormone
(FSH), prolactin (PRL), estradiol (E2),progesterone (PROG), testosterone (TESTO), and dehydroepiandrosterone (DHEA)
were conducted. Serum RBP4 was detected by an enzyme immunoassay kit and validated by quantitative Western
blotting.
Results: Circulating RBP4 levels were positively associated with BMI, waist circumference, waist-to-hip ratio (WHR),
systolic and diastolic (SBP), diastolic blood pressure (DBP), triglycerides (TG), low high-density lipoprotein
cholesterol(LDL-c), and testosterone (TESTO) in the total group. While only in obese individuals, serum RBP4
levels were negatively associated with E2. The highest value was in the subjects with both obesity and the low
estrogen level. Multiple linear regression analysis revealed that RBP4 correlated independently with TG, TC and
insulin in all subjects, TC in non- obese individuals. However, E2 were significantly associated with serum RBP4
only in obese individuals.
Conclusions: RBP4 could be a marker of obesity-related factors; estrogen was negatively related to RBP4 and might
be one of the influential factors.
Keywords: Retinol binding protein 4, Estrogen, Obesity
Background
Retinol-binding protein 4 (RBP4), belongs to the lipoca-
lin family of proteins, which is released primarily by the
liver, has also been shown to be released by adipose tis-
sue as the second highest rate of expression [1, 2]. In
humans, serum RBP4 levels have been suggested to
provide the association with the degree of adiposity [3].
Obesity is associated with a dramatic increase in the
prevalence of type 2 diabetes, and also has been associ-
ated with many other chronic diseases and comorbidi-
ties. Over the past few decades, the prevalence of obesity
has increased greatly worldwide and in China, especially
[4, 5]. Thus, the prevention of obesity among people
should be considered a priority of health care policy.
Several studies show that serum RBP4 levels correlate
inversely with the severity of insulin sensitivity, which is
positively with obesity and type 2 diabetes, as well as
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components of the metabolic syndrome, and can be used
as a noninvasive serological indexes reflecting the meta-
bolic abnormalities [6–8]. However, there is also conflict-
ing data between RBP4 and obesity was demonstrated in
other studies [9, 10]. Therefore, the relationship of RBP4
and obesity is still controversial in adult. RBP4 does not
reach adult plasma levels until puberty, after which plasma
levels are changeable, based on the menstrual cycle. And
this variation in the plasma RBP level appears to correlate
with peak levels of estradiol and menopausal status in
women [11, 12]. It also has been proved that plasma RBP4
concentration varies by gender, generally being lower in
women than in men participants. Several previous studies
hypothesized that sex hormones may play a role in the dif-
ference [10, 12, 13]. So it is necessary to investigate the
participation of sex hormones on the levels of RBP4 in
humans, especially in woman.
Therefore, the major aim of the present study is to
evaluate the association between RBP4 levels, obesity,
sex hormones, as well as other metabolic parameters in
Chinese women. Additionally, we sought to explore the




We consecutively selected 138 subjects from the general
population who had undergone medical check-ups at the
outpatient department of Endocrinology of Zhongshan
hospital, Fudan university from Oct.2013 and Aug.2014.
After excluding 51 of the 138 subjects, a total of 87
subjects were enrolled in our study. Exclusion factors
were diseases affecting the metabolic state or not suit-
able to participate in this study. Women presenting
endometriosis, uterinefibroid, breast cancer and those
with hormone-dependent cancer were excluded. Hyper-
thyroidism, hypothyroidism, diabetes, mental disease,
serious disease with dysfunction of heart, liver, kidney,
were excluded as well as those using estrogen replace-
ment therapy. The study was approved by the human
research ethics committee of Zhongshan hospital,
Fudan University and informed consent was obtained
from all subjects.
Anthropometric and biochemical measurements
Height (cm) and weight (kg) of participants, wearing
light clothing and without shoes, was measured with sta-
diometers and calibrated balance-beam scales, respect-
ively. BMI was calculated as weight in kilograms divided
by the square of height in meters. Waist circumference
(cm) was measured with a non-stretchable tape at the
end of a normal expiration, at the smallest horizontal cir-
cumference between the ribs and iliac crest. Thus, waist–
hip ratio (WHR) was calculated as waist circumference
divided by hip circumference. Blood pressure was mea-
sured in the right arm in the seated position, after at least
a 5 min rest, and the average of the three blood pressures
was used as the final blood pressure. Blood samples were
collected after a fasting period of at least 10 h overnight.
Serum total cholesterol (TC), triglycerides (TG), high-
density lipoprotein cholesterol (HDL-c), and low-density
lipoprotein cholesterol (LDL-c) were determined by en-
zymatic methods with a Hitachi 7600 analyzer (Hita-
chi,Ltd. Tokyo, Japan). Serum insulin (mU/L) was
measured with an insulin radioimmunoassay kit (kit from
Beijing North Biotechnology Research Institute). Follicle
stimulating hormone (FSH), luteinizing hormone (LH),
prolactin (PRL), estradiol (E2), progesterone (PROG), tes-
tosterone (TESTO), dehydroepiandrosterone (DHEA)
were checked. Methods for measuring blood hormones
were electrochemiluminescence immunoassay (ECLIA),
and kits were used for ECLIA supplied by Roche Diagnos-
tic Systems, GmbH,Mannheim, Germany. Serum RBP4
(μg/ml) was measured in duplicate by a sandwich ELISA
developed in-house, using affinity chromatography puri-
fied polyclonal and monoclonal antibodies generated
against recombinant human RBP4 protein. The assay sys-
tem was subsequently cross validated by Western blot
analysis [14]. According to recommendations of the
Working Group on Obesity in China, BMI between 18.5
and 24.0kg/m2 was considered normal. BMI between 24.0
and 28.0kg/m2 was defined as overweight, and over 28.0
was defined as obesity [15].
Statistical analyses
Mean (standard deviation), median (interquartile range),
were tabulated for demographic, and laboratory charac-
teristics by BMI. Differences in the distributions of these
variables between non-obese and obese were calculated
by the Chi-Square test for categorical variables, ANOVA
for normally distributed continuous variables. Following
this, Pearson’s correlation was used to examine the asso-
ciation of serum RBP4 and other parameters. Multiple
testing was corrected using LSD method (Equal Vari-
ances Assumed) or Games-Howell method (Equal Var-
ance not assumed). Multiple stepwise regression analysis
was used to examine the association of estrogen and
serum RBP4 and other parameters. All statistical ana-
lyses were performed using SPSS18.0 (SPSS Inc., Chi-
cago, Illinois, USA), p values <0.05 were considered
significant.
Results
The mean age of study participants was 40.22±15.54
years. Demographic and laboratory characteristics strati-
fied by BMI are presented in Table 1. Compared to non-
obese, obese individuals had higher waist circumference,
hip circumference, waist-to-hip ratio (WHR), systolic
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and diastolic (SBP), diastolic blood pressure (DBP), tri-
glycerides (TG), but lower high-density lipoprotein chol-
esterol (HDL-c), luteinizing hormone (LH), and follicle
stimulating hormone (FSH). There are no differences be-
tween non-obese and obese individuals in age, total
cholesterol (TC), low high-density lipoprotein cholester-
ol(LDL-c), prolactin (PRL), estradiol (E2), progesterone
(PROG), testosterone (TESTO), dehydroepiandrosterone
(DHEA), fasting insulin and serum RBP4.
The Pearson correlation coefficients for associations
between RBP4 concentrations and other parameters are
summarized in Table 2. In all subjects, serum RBP4
levels were significantly positively associated with BMI,
waist circumference, WHR, SBP, DBP, TC, TG, LDL-c
and TESTO, but not associated with hip circumference,
HDL-c, LH, FSH, PRL, E2, PROG and DHEA. In non-
obese individuals, serum RBP4 levels were significantly
positively associated with BMI, SBP, TC, TG, LDL-c, but
not associated with waist circumference, hip circumfer-
ence, DBP and the other variables mentioned above.
However, in obese individuals, serum RBP4 levels were
significantly positively associated with TC, TG, TESTO,
and DHEA, whereas negatively associated with insulin
and E2. But not associated with BMI, WHR and the
other variables mentioned above, either.
Especially, we found that Serum RBP4 level was nega-
tively correlated with estrogen in obese individuals (r =
−0.374, p = 0.032), but no longer existed when in non-
obese individuals (r = −0.01, p = 0.962) (Fig. 1). To fur-
ther explore the association among serum RBP4 levels,
BMI and E2, we built interaction terms between serum
RBP4 levels and two categories of BMI and estradiol
(E2) stratified by the median values at the same time.
There were significant differences in serum RBP4 levels
between groups classified by E2 level within the same
BMI strata (Table 3). RBP4 levels were the highest in the
subjects with both obesity and the low estrogen level
(37.08 ± 7.29 μg/ml vs. 26.77 ± 3.47 μg/ml, 29.64 ± 7.8
μg/ml, and 30.9 ± 7.18 μg/ml, P for trend <0.001, re-
spectively), compare to those with neither obesity nor
low estrogen levels, individuals with no-obese but low
estrogen levels, and individuals with obesity but high es-
trogen levels.
A stepwise multiple linear regression analysis was per-
formed using serum RBP4 level as a dependent variable.
Independent variables were those parameters, which
Table 1 Basic characteristics of all the subjects
Non-obese (n = 45) Obese (n = 42) P value
Age (year) 41.18 (16.07) 39.19 (15.08) 0.554
BMI (kg/m2) 22.69 (3.68) 34.79 (4.99) <0.001
Waist (cm) 82.49 (10.55) 110.48 (14.53) <0.001
Hip (cm) 94.09 (7.18) 116.65 (10.69) <0.001
WHR (cm/cm) 0.88 (0.08) 0.95 (0.08) <0.001
SBP (mmHg) 118.00 (16.67) 129.76 (16.7) 0.002
DBP (mmHg) 75.52 (8.55) 81.95 (11.92) 0.005
TC(mmol/L) 4.35 (0.94) 4.54 (0.83) 0.326
TG (mmol/L) 1.23 (0.70) 1.70 (0.90) 0.008
HDL-c (mmol/L) 1.27 (0.40) 1.02 (0.25) 0.001
LDL-c (mmol/L) 2.53 (0.81) 2.76 (0.70) 0.155
LH (mIU/mL) 8.00 (0.30–59.70) 5.70 (0.30–59.70) 0.018
FSH (mIU/mL) 5.60 (0.10–114.30) 5.30 (0.20–69.7) 0.046
PRL(mIU/mL) 380.60 (23.60–9544.00) 381.65 (10.40–2042.00) 0.562
E2 (pmol/L) 114.70 (22.20–617.60) 135.80 (37.20–859.90) 0.661
PROG (nmol/L) 1.40 (0.10–37.55) 1.40 (0.20–21.27) 0.733
TESTO (nmol/L) 0.99 (0.10–23.50) 1.78 (0.30–25.90) 0.510
DHEA (umol/L) 2.85 (0.40–16.70) 4.20 (1.20–18.50) 0.071
Fasting insulin (mU/L) 9.50 (5.00–57.20) 15.50 (3.60–60.50) 0.295
Serum RBP4 (μg/ml) 30.07 (7.83) 33.07 (7.06) 0.064
Data are presented as means(S.D) or median (range)
BMI body-mass index, SBP systolic blood pressure, DBP diastolic blood pressure, WHR waist-to-hip ratio, TC total cholesterol, TG triglycerides, HDL-c high-density
lipoprotein cholesterol, LDL-c low-density lipoprotein cholesterol, LH luteinizing hormone, FSH folliclestimulating hormone, PRL prolactin, E2 estradiol, PROG
progesterone, TESTO testosterone, DHEA dehydroepiandrosterone, RBP4 retinol binding protein 4
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were significantly associated with RBP4 in Pearson’s cor-
relation analysis. In all subjects, TG (Standardized Coef-
ficients Beta = 0.509, P <0.001), TC (Standardized
Coefficients Beta = 0.260, P = 0.047) together with Insu-
lin (Standardized Coefficients Beta = −0.249, p = 0.035)
were independent variables significantly associated with
serum RBP4. In non-obese individuals, TC (Standardized
Coefficients Beta = 0.582, P = 0.006) was independently
associated with serum RBP4, while in obese individuals,
Insulin (Standardized Coefficients Beta = −0.518, p =
0.006) together with E2 (Standardized Coefficients Beta
= −0.438, p = 0.013) were significantly associated with
serum RBP4 (Table 4).
Discussion
In the current study, we found that serum RBP4 levels
were inversely associated with E2 levels in a cohort of
Chinese women patients with obesity. To the best of our
knowledge, this study is the first showing that circulating
RBP4 is associated not only with BMI but also E2 levels
in Chinese women patients, which implied that estradiol
might be an impact factor on the relation between obes-
ity and circulating RBP4.
RBP4 has long-been known to be released by the liver,
and it also has been shown that approximately 15% of
circulating secretion results from adipose tissue, and
down-regulates the glucose transporter GLUT4, which
acts as the rate-limiting step in insulin-activated glucose
transport across both muscle and adipocyte membranes
[16, 17]. Results from the previous study also suggested
that RBP4 levels had an important effect on obesity indi-
ces, as measured by BMI, WC, waist-to-hip ratio, and
even body fat percentage [10, 14, 18, 19]. Especially, a
Table 2 Pearson’s correlation analysis of serum RBP4 in all the
subjects
Total (n = 87) Non-obese (n = 45) Obese (n = 42)
r P r P r P
BMI 0.308** 0.004 0.377* 0.011 0.158 0.316
Waist 0.258* 0.025 0.189 0.277 0.097 0.553
Hip 0.188 0.107 0.147 0.400 −0.070 0.666
WHR 0.271* 0.019 0.136 0.436 0.260 0.105
SBP 0.302** 0.005 0.352* 0.019 0.139 0.386
DBP 0.270* 0.013 0.276 0.069 0.198 0.214
TC 0.422** P <0.001 0.467** 0.001 0.337* 0.029
TG 0.497** P <0.001 0.315* 0.037 0.619** P <0.001
HDL −0.078 0.476 0.061 0.693 −0.129 0.415
LDL 0.295** 0.006 0.388** 0.009 0.115 0.468
LH 0.110 0.317 0.238 0.125 0.025 0.877
FSH 0.148 0.171 0.267 0.076 0.053 0.737
PRL −0.151 0.166 −0.132 0.398 −0.255 0.103
E2 −0.207 0.113 −0.01 0.962 −0.374* 0.032
PROG −0.119 0.298 −0.018 0.910 −0.317 0.063
TESTO 0.229* 0.045 0.102 0.541 0.344* 0.032
DHEA 0.210 0.055 0.050 0.747 0.329* 0.038
INSUL −0.262 0.079 −0.258 0.418 −0.423* 0.013
*P <0.05; **P <0.01
BMI body-mass index, SBP systolic blood pressure, DBP diastolic blood pressure,
WHR waist-to-hip ratio, TC total cholesterol, TG triglycerides, HDL-c high-density
lipoprotein cholesterol, LDL-c low-density lipoprotein cholesterol, LH luteinizing
hormone, FSH folliclestimulating hormone, PRL prolactin, E2 estradiol, PROG
progesterone, TESTO testosterone, DHEA dehydroepiandrosterone, RBP4 retinol
binding protein 4
Fig. 1 Pearson’s correlation analysis between RBP4 ((μg/ml)) and E2(pmol/L). Serum RBP4 level was negatively correlated with estrogen in obese
individuals (r = −0.374, p = 0.032, a However, the association between RBP4 and estrogen no longer existed when in non-obese individuals
(r = −0.01, p = 0.962, b)
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prospective study suggested that baseline RBP4 levels
predict subsequent increase in WC in a Korean adoles-
cent population [20]. Similar to prior studies in adults,
we found that the RBP4 levels were positively correlated
with most of the obesity indices in Chinese women, in-
cluding BMI, waist circumference, and WHR in the
whole subjects. The results mentioned above indicate
that RBP4 might be a useful marker of obesity-related
factors in subjects. There are some discrepant results
from other studies have questioned these associations,
failing to demonstrate associations with obesity [21–23].
The possible reasons for this difference may due to dif-
ferent study subjects in the ethnicity, age, and size of the
samples. However, when all women were divided into
different groups according to BMI, there are no differ-
ences between non-obese and obese individuals in serum
RBP4 levels. And the same link between circulating
RBP4 levels and obesity indices was not founded in
obese women, which implied that there are other mech-
anisms for regulating RBP4 levels.
In both adults and children, the concentration of
serum RBP4 varies by gender, with levels lower in female
than in male participants [13, 24, 25]. Several previous
studies supported that RBP4 levels were shown to be dif-
ferent between premenopausal and postmenopausal
women and vary according to menstrual cycle [11, 25,
26]. It hypothesized that sex hormones may play a role
in the gender discrepancy, which may also plays protect-
ive effect on women against the influence of RBP4. In
our result, we found that serum RBP4 levels were signifi-
cantly negatively associated with estrogen (E2) only in
obese women. When subjects were divided into four
groups according to BMI and estrogen (E2) stratified by
the median values, the highest value for serum RBP4
was in subjects with both obesity and the low estrogen
level, the lowest value was in non-obese groups with
high estrogen level. Multiple linear regression analysis
also revealed that RBP4 correlated independently with
TG, TC and insulin in all subjects, however, with E2 only
in obese individuals. The possible mechanisms are as fol-
low. Firstly, estrogen may have a direct effect on serum
RBP4 expression. Tan et al found the RBP4 level is influ-
enced by the effect of sex hormones and suggested 17b-
estradiol have a direct regulatory effecting on the RBP4
concentration in women with polycystic ovary syndrome
[27]. Other researches indicated estrogen mediates retin-
oic acid metabolism by the regulation of RBP4 expression
in adipose tissue, and the systemic deficiency of serum es-
trogen may activate a specific regulatory process and con-
sequently, which induce the overexpression of RBP4
through ER in visceral adipocytes [28, 29]. Secondly, estro-
gen may convey an indirect effect by influencing the body
fat distribution on serum RBP4. As one kind of adipocyto-
kines, RBP4 was identified a sexual dimorphism for secre-
tion in previous studies, which was partly attributed to the
effect of sex hormones and body fat distribution [30, 31].
Estrogen has an important role in regulation of fat metab-
olism, and the effect of estrogen to reduction of lipolysis
was through activation of estrogen receptor alpha (ER-α)
in adipose tissue, then influenced body adiposity [32–34].
Lack of estrogen, people tend to accrue more visceral fat,
which has been highly correlated to metabolic and cardio-
vascular risk; whereas accrue less fat in the subcutaneous
depot [35]. In our previous study, we have found that cir-
culating RBP4 is positively associated with the visceral fat,
which implied that visceral fat might be a major source of
excess circulating RBP4 [36]. Consistent with our findings,
relationship of RBP4 and visceral fat, not subcutaneous
fat, was confirmed by many other studies in different pop-
ulations [37–39], which suggest that visceral obesity might
play a key role in increasing the circulating RBP4 level.
Therefore, when combining several factors, the group with
both obesity and low estrogen level has the highest serum
RBP4 levels. We also found that testosterone was posi-
tively associated with RBP4 levels in women, for DHEA
only in obese women.
Table 3 The mean concentration of RBP4 in women stratified by BMI and estradiol (E2) levels
Non-obese Obese
E2 >118.60 (pmol/L) E2 <118.60 (pmol/L) E2 >118.60 (pmol/L) E2 <118.60 (pmol/L)a,b,c
26.77 ± 3.47 (μg/ml) 29.64 ± 7.80 (μg/ml) 30.9 ± 7.18 (μg/ml) 37.08 ± 7.29 (μg/ml)
aP <0.05 vs Non-obese group with high E2 level
bP <0.05 vs Non-obese group with low E2 level
cP <0.05 vs Obese group with high E2 level
E2 corresponds to baseline estradiol levels. Cut-off point was set at median value
Table 4 Multiple linear regression analysis of RBP4 and other
parameters
Standardized coefficients beta t Sig
ALL TG 0.509 4.651 P <0.001
TC 0.260 2.098 0.047
INSUL −0.249 −2.240 0.035
Non-obese TC 0.582 3.113 0.006
Obese E2 −0.438 −2.723 0.013
INSUL −0.518 −3.087 0.006
A step-wise multiple linear regression analysis was performed to determine
the contributing factors to serum RBP4 levels. Independent variables included
in multivariate regression model were variables which significantly associated
with RBP4 in Pearson’s correlation analysis
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The close relationship between other metabolic parame-
ters and RBP4 in adult and adolescents has been observed
in previous studies, in which RBP4 was positively associ-
ated with BP, lipid profiles, and FPG [20, 26, 40]. We also
found that the RBP4 levels were positively correlated with
most of the cardiometabolic risk factors, such as SBP,
DBP, TC, TG and LDL. Especially, circulating RBP4 levels
were found to be highly correlated with TC and TG, both
in non-obese and obese subject. Consistent with our re-
sult, another research found higher triglyceride levels is
correlated with higher RBP4 [41]. The possible mechan-
ism is that retinoid have been known to affect the expres-
sion of several genes involved in triglyceride metabolism,
including regulators of apo C-III production, hepatic and
gastrointestinal triglyceride production and secretion, and
beta-oxidation of fatty acids [42].
Some limitations of this study must be taken into con-
sideration. Firstly, the cross-sectional design of the study
represents a limitation, implicating that cause-and-effect
relationship cannot be discerned. Secondly, our study
subjects included only from the outpatient women. And
the majority of individuals are middle-aged woman with
variation of plasma estrogen, which may influence the
levels of RBP4, as it changed during the menstrual cycle.
The relation of RBP4 and estrogen is also restricted to
only in obese women. Therefore, our results may not be
applicable to the whole population. Finally, due to the
limitation of data collection on all types of sex hor-
mones, we got small sample size. As well as being small,
the trials may have methodological weaknesses that
could have resulted in bias.
Conclusion
In conclusion, RBP4 could be a marker of obesity-related
risk factors, and it is negatively related to estrogen, restricted
to obese individuals. The RBP4 levels were higher in the co-
presence of obesity and low estrogen, which suggested that
their relationship was complicated and might influenced by
estrogen and other confounding factors. Further experi-
ments with larger groups of subjects are warranted to clarify
the relationship between RBP4 and estrogen.
Abbreviations
RBP4: retinol binding protein 4; BMI: body-mass index; SBP: systolic blood
pressure; DBP: diastolic blood pressure; WHR: waist-to-hip ratio; TC: total
cholesterol; TG: triglycerides; HDL-c: high-density lipoprotein cholesterol;
LDL-c: low-density lipoprotein cholesterol; LH: luteinizing hormone;
FSH: folliclestimulating hormone; PRL: prolactin; E2: estradiol; PROG: progesterone;
TESTO: testosterone; DHEA: dehydroepiandrosterone.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
XG and HY designed the research and revised the manuscript; QL and WW
carried out the experiment and wrote the paper; MX and HB collected samples
and took charge of detection of serum RBP4; HL and XC participated in data
analysis; all authors have read and approved the final version of the manuscript.
Authors’ information
Qian Li and Weiyun Wu are the co first author.
Acknowledgements
We thank Prof. Pu Xia for critical reading and editing the manuscript and the
colleagues in Zhongshan Hospital, Fudan University for assistance in
recruiting patients to the study.
This study was supported by grants from the National Natural Science
Foundation for young scholar,China (Grant 81200627 to Hongmei YAN), the
Shanghai Municipal Health Project Grant (grant no. 2013ZYJB0802 to X. Gao),
and the Shanghai Health and Family Planning Commission Foundation
(2013SY005 to X. Gao).
Author details
1Department of Endocrinology and Metabolism, Shanghai Zhongshan
Hospital, Fudan University, Shanghai 200032, China. 2Department of Clinical
Laboratory, Shanghai Zhongshan Hospital, Fudan University, Shanghai
200032, China.
Received: 31 December 2015 Accepted: 25 February 2016
References
1. Wongsiriroj N, Jiang H, Piantedosi R, Yang KJ, Kluwe J, Schwabe RF, et al.
Genetic dissection of retinoid esterification and accumulation in the liver
and adipose tissue. J Lipid Res. 2014;55(1):104–14.
2. Blaner WS. Retinol-binding protein: the serum transport protein for vitamin
A. Endocr Rev. 1989;10(3):308–16.
3. Zabetian-Targhi F, Mahmoudi MJ, Rezaei N, Mahmoudi M. Retinol binding
protein 4 in relation to diet, inflammation, immunity, and cardiovascular
diseases. Adv Nutr. 2015;6(6):748–62.
4. Li TY, Rana JS, Manson JE, Willett WC, Stampfer MJ, Colditz GA, et al. Obesity
as compared with physical activity in predicting risk of coronary heart
disease in women. Circulation. 2006;113(4):499–506.
5. Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and
obesity as determinants of cardiovascular risk: the Framingham experience.
Arch Intern Med. 2002;162(16):1867–72.
6. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, et al.
Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic
subjects. N Engl J Med. 2006;354(24):2552–63.
7. Gavi S, Stuart LM, Kelly P, Melendez MM, Mynarcik DC, Gelato MC, et al.
Retinol-binding protein 4 is associated with insulin resistance and body fat
distribution in nonobese subjects without type 2 diabetes. J Clin Endocrinol
Metab. 2007;92(5):1886–90.
8. Sun Q, Kiernan UA, Shi L, Phillips DA, Kahn BB, Hu FB, et al. Plasma retinol-
binding protein 4 (RBP4) levels and risk of coronary heart disease: a
prospective analysis among women in the nurses’ health study. Circulation.
2013;127(19):1938–47.
9. Janke J, Engeli S, Boschmann M, Adams F, Bohnke J, Luft FC, et al. Retinol-
binding protein 4 in human obesity. Diabetes. 2006;55(10):2805–10.
10. Santoro N, Perrone L, Cirillo G, Brienza C, Grandone A, Cresta N, et al.
Variations of retinol binding protein 4 levels are not associated with
changes in insulin resistance during puberty. J Endocrinol Invest. 2009;
32(5):411–4.
11. Jia J, Bai J, Liu Y, Yin J, Yang P, Yu S, et al. Association between retinol-
binding protein 4 and polycystic ovary syndrome: a meta-analysis. Endocr J.
2014;61(10):995–1002.
12. An C, Wang H, Liu X, Li Y, Su Y, Gao X, et al. Serum retinol-binding protein 4
is elevated and positively associated with insulin resistance in
postmenopausal women. Endocr J. 2009;56(8):987–96.
13. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, et al. Plasma retinol-
binding protein-4 concentrations are elevated in human subjects with impaired
glucose tolerance and type 2 diabetes. Diabetes Care. 2006;29(11):2457–61.
14. Qi Q, Yu Z, Ye X, Zhao F, Huang P, Hu FB, et al. Elevated retinol-binding
protein 4 levels are associated with metabolic syndrome in Chinese people.
J Clin Endocrinol Metab. 2007;92(12):4827–34.
15. Gordon-Larsen P, Wang H, Popkin BM. Overweight dynamics in Chinese
children and adults. Obes Rev. 2014;15 Suppl 1:37–48.
16. Wolf G. Serum retinol-binding protein: a link between obesity, insulin
resistance, and type 2 diabetes. Nutr Rev. 2007;65(5):251–6.
Li et al. Lipids in Health and Disease  (2016) 15:52 Page 6 of 7
17. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al.
Serum retinol binding protein 4 contributes to insulin resistance in obesity
and type 2 diabetes. Nature. 2005;436(7049):356–62.
18. Aeberli I, Biebinger R, Lehmann R, L’Allemand D, Spinas GA, Zimmermann
MB. Serum retinol-binding protein 4 concentration and its ratio to serum
retinol are associated with obesity and metabolic syndrome components in
children. J Clin Endocrinol Metab. 2007;92(11):4359–65.
19. Kowalska I, Straczkowski M, Adamska A, Nikolajuk A, Karczewska-Kupczewska
M, Otziomek E, et al. Serum retinol binding protein 4 is related to insulin
resistance and nonoxidative glucose metabolism in lean and obese women
with normal glucose tolerance. J Clin Endocrinol Metab. 2008;93(7):2786–9.
20. Choi KM, Yannakoulia M, Park MS, Cho GJ, Kim JH, Lee SH, et al. Serum
adipocyte fatty acid-binding protein, retinol-binding protein 4, and
adiponectin concentrations in relation to the development of the metabolic
syndrome in Korean boys: a 3-y prospective cohort study. Am J Clin Nutr.
2011;93(1):19–26.
21. Kanaka-Gantenbein C, Margeli A, Pervanidou P, Sakka S, Mastorakos G,
Chrousos GP, et al. Retinol-binding protein 4 and lipocalin-2 in childhood
and adolescent obesity: when children are not just “small adults”. Clin
Chem. 2008;54(7):1176–82.
22. Broch M, Vendrell J, Ricart W, Richart C, Fernandez-Real JM. Circulating
retinol-binding protein-4, insulin sensitivity, insulin secretion, and insulin
disposition index in obese and nonobese subjects. Diabetes Care.
2007;30(7):1802–6.
23. Lewis JG, Shand BI, Frampton CM, Elder PA, Scott RS. Plasma retinol-binding
protein is not a marker of insulin resistance in overweight subjects: a three
year longitudinal study. Clin Biochem. 2008;41(13):1034–8.
24. Lee DC, Lee JW, Im JA. Association of serum retinol binding protein 4 and
insulin resistance in apparently healthy adolescents. Metabolism. 2007;56(3):
327–31.
25. Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D.
Reduction of elevated serum retinol binding protein in obese children by
lifestyle intervention: association with subclinical inflammation. J Clin
Endocrinol Metab. 2007;92(5):1971–4.
26. Chan TF, Tsai YC, Chiu PR, Chen YL, Lee CH, Tsai EM: Serum retinol-binding
protein 4 levels in nonobese women with polycystic ovary syndrome. Fertil
Steril. 2010;93(3):869–73.
27. Tan BK, Chen J, Lehnert H, Kennedy R, Randeva HS. Raised serum,
adipocyte, and adipose tissue retinol-binding protein 4 in overweight
women with polycystic ovary syndrome: effects of gonadal and adrenal
steroids. J Clin Endocrinol Metab. 2007;92(7):2764–72.
28. Yi KW, Shin JH, Seo HS, Lee JK, Oh MJ, Kim T, et al. Role of estrogen
receptor-alpha and -beta in regulating leptin expression in 3T3-L1
adipocytes. Obesity (Silver Spring). 2008;16(11):2393–9.
29. Matsuda M, Masui F, Mori T. Neonatal estrogenization leads to increased
expression of cellular retinol binding protein 2 in the mouse reproductive
tract. Cell Tissue Res. 2004;316(1):131–9.
30. Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, Jimenez-Chillaron JC,
et al. Sexual differentiation, pregnancy, calorie restriction, and aging affect the
adipocyte-specific secretory protein adiponectin. Diabetes. 2003;52(2):268–76.
31. Rosenbaum M, Pietrobelli A, Vasselli JR, Heymsfield SB, Leibel RL. Sexual
dimorphism in circulating leptin concentrations is not accounted for by
differences in adipose tissue distribution. Int J Obes Relat Metab Disord.
2001;25(9):1365–71.
32. Van Pelt RE, Gozansky WS, Hickner RC, Schwartz RS, Kohrt WM. Acute
modulation of adipose tissue lipolysis by intravenous estrogens. Obesity
(Silver Spring). 2006;14(12):2163–72.
33. Pedersen SB, Kristensen K, Hermann PA, Katzenellenbogen JA, Richelsen B.
Estrogen controls lipolysis by up-regulating alpha2A-adrenergic receptors
directly in human adipose tissue through the estrogen receptor alpha.
Implications for the female fat distribution. J Clin Endocrinol Metab.
2004;89(4):1869–78.
34. Morselli E, Fuente-Martin E, Finan B, Kim M, Frank A, Garcia-Caceres C, et al.
Hypothalamic PGC-1alpha protects against high-fat diet exposure by
regulating ERalpha. Cell Rep. 2014;9(2):633–45.
35. Palmer BF, Clegg DJ. The sexual dimorphism of obesity. Mol Cell Endocrinol.
2015;402:113–9.
36. Chang X, Yan H, Bian H, Xia M, Zhang L, Gao J, et al. Serum retinol binding
protein 4 is associated with visceral fat in human with nonalcoholic fatty
liver disease without known diabetes: a cross-sectional study. Lipids Health
Dis. 2015;14:28.
37. Kloting N, Graham TE, Berndt J, Kralisch S, Kovacs P, Wason CJ, et al. Serum
retinol-binding protein is more highly expressed in visceral than in
subcutaneous adipose tissue and is a marker of intra-abdominal fat mass.
Cell Metab. 2007;6(1):79–87.
38. Lee JW, Im JA, Lee HR, Shim JY, Youn BS, Lee DC. Visceral adiposity is
associated with serum retinol binding protein-4 levels in healthy women.
Obesity (Silver Spring). 2007;15(9):2225–32.
39. Jia W, Wu H, Bao Y, Wang C, Lu J, Zhu J, et al. Association of serum retinol-
binding protein 4 and visceral adiposity in Chinese subjects with and
without type 2 diabetes. J Clin Endocrinol Metab. 2007;92(8):3224–9.
40. Kim IK, Lee HJ, Kang JH, Song J. Relationship of serum retinol-binding
protein 4 with weight status and lipid profile among Korean children and
adults. Eur J Clin Nutr. 2011;65(2):226–33.
41. Goodman E, Graham TE, Dolan LM, Daniels SR, Goodman ER, Kahn BB. The
relationship of retinol binding protein 4 to changes in insulin resistance and
cardiometabolic risk in overweight black adolescents. J Pediatr. 2009;154(1):
67–73.
42. Staels B. Regulation of lipid and lipoprotein metabolism by retinoids. J Am
Acad Dermatol. 2001;45(5):S158–67.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Li et al. Lipids in Health and Disease  (2016) 15:52 Page 7 of 7
